Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.68 and traded as high as $0.6870. Xtant Medical shares last traded at $0.63, with a volume of 332,254 shares trading hands.

Analyst Ratings Changes

Separately, BTIG Research reduced their price target on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $1.50.

Xtant Medical Stock Performance

The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35. The firm has a market cap of $88.20 million, a P/E ratio of 63.06 and a beta of -0.08. The business has a fifty day simple moving average of $0.69 and a 200-day simple moving average of $0.68.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Monday, November 10th. The medical device company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%. The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $32.70 million.

Institutional Trading of Xtant Medical

A number of hedge funds have recently made changes to their positions in XTNT. Nantahala Capital Management LLC grew its stake in shares of Xtant Medical by 500.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Xtant Medical in the second quarter worth $4,875,000. Vanguard Group Inc. grew its stake in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the last quarter. Crescent Grove Advisors LLC increased its holdings in shares of Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Mink Brook Asset Management LLC raised its position in shares of Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. 69.33% of the stock is owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.